1. In Vivo

Orthopedics at a Crossroads

It's been over a year since VHA launched its orthopedic implant program-and nearly two years since Premier launched its program. To date, neither program has delivered the kinds of business, say insiders, that their manufacturer partners had hoped for. Unless a hospital group owns its hospitals, getting compliance is too difficult.

It's been over a year since VHA launched its orthopedic implant program—and nearly two years since Premier launched its program. To date, neither program has delivered the kinds of business, say insiders, that their manufacturer partners had hoped for, reinforcing the sentiment in some circles of the orthopedics industry that unless a hospital group owns its hospitals, getting compliance on these contracts is too difficult.

DePuy's decision earlier this fall to end its participation in the VHA program underscores the compliance issue for implant companies....

More from Archive

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By David Wild

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.